603229.SS
603229.SS
CNE100002XK2
ZHEJIANG AUSUN PHARMACEUTICAL C
Loading chart...

Company Profile

Zhejiang Ausun Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical formulations, specialty active pharmaceutical ingredients (APIs), and pharmaceutical intermediates in China and internationally. The company offers products for liver diseases, respiratory system diseases, cardiovascular and cerebrovascular diseases, high-end fluorine products, prostaglandins, antibacterial agents, gout, anti-tumor treatments, and nervous system disorders. It also provides customized contract research, development, and manufacturing services. In addition, the company engages in technology research and development, commissioned technology development, technology transfer, consulting, and promotion services; wholesale of organic intermediates; medical research and experimental development; market research; conference services; organization of exhibitions and displays; import and export trade of pharmaceuticals, food, cosmetics, medical devices, goods and technology, and related instruments and equipment; drug clinical trials; retail of pharmaceuticals; technical consultation and exchange; health consultation; and research and development of biochemical products. Zhejiang Ausun Pharmaceutical Co., Ltd. was incorporated in 2010 and is headquartered in Taizhou, China.

Related stocks

9887.HK
9887.HK • China
LEADS BIOLABS-B
45.56 HKD
1.15B USD 1Y -37.5%
1952.HK
1952.HK • China
EVEREST MED
29.6 HKD
1.33B USD 1Y -47.1%
2595.HK
2595.HK • China
GENFLEET-B
28.6 HKD
1.4B USD 1Y -21%
2157.HK
2157.HK • China
LEPU BIO
3.82 HKD
878.4M USD 1Y -47.2%
600645.SS
600645.SS • China
VCANBIO CELL & GENE ENG CORP LT
19.1 CNY
1.34B USD 1Y -22%
300049.SZ
300049.SZ • China
FRMS CO., LTD
40.49 CNY
1.6B USD 1Y -44.3%
2617.HK
2617.HK • China
TRANSTHERA-B
10.43 HKD
541.23M USD 1Y -92.1%
2616.HK
2616.HK • China
CSTONE PHARMA-B
5.09 HKD
1.03B USD 1Y -33.8%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
50.0% p.a.
Max Drawdown (5Y)
-80.9%
Sharpe Ratio (5Y)
-0.12
Beta Factor
-0.22
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 74.5 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (50.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -80.9% in the extended horizon.
ende